Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Zhengrong Zhou

Matched on ORCID iD 0000-0002-9922-1000; OpenAlex author ID A5101420170. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
14
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: 3 papers · 2026: 2 papers

Papers 13

  1. Correction: Dual-energy CT extracellular volume fraction predicts tumor collagen ratio and possibly survival for inoperable pancreatic cancer patients. Last author DOI 10.1007/s00330-025-12025-x↗
  2. Spectral CT-Based habitat imaging for the prediction of occult lymph node metastasis in resectable pancreatic ductal Adenocarcinoma: Pathological validation vi… Last author DOI 10.1016/j.ejrad.2026.112679↗
  3. The preoperative prediction of lymph node metastasis of resectable pancreatic ductal adenocarcinoma using dual-layer spectral computed tomography. Co-author DOI 10.1007/s00330-024-11143-2↗
  4. Dual-energy CT extracellular volume fraction predicts tumor collagen ratio and possibly survival for inoperable pancreatic cancer patients. Last author DOI 10.1007/s00330-024-11330-1↗
  5. Integrating radiomics and 3D bioprinted tumor model: the next-generation approach to improve pancreatic cancer treatment. Last author DOI 10.21037/hbsn-2025-676↗
  6. Dual-layer spectral detector CT: A noninvasive preoperative tool for predicting histopathological differentiation in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ejrad.2024.111327↗
  7. Value of diffusion kurtosis MR imaging and conventional diffusion weighed imaging for evaluating response to first-line chemotherapy in unresectable pancreatic… Last author DOI 10.1186/s40644-024-00674-y↗
  8. Pancreatic ductal adenocarcinoma: a radiomics nomogram outperforms clinical model and TNM staging for survival estimation after curative resection. Last author DOI 10.1007/s00330-019-06600-2↗
  9. LncRNA XIST promotes pancreatic cancer migration, invasion and EMT by sponging miR-429 to modulate ZEB1 expression. Co-author DOI 10.1016/j.biocel.2019.05.021↗
  10. Dynamic contrast-enhanced magnetic resonance imaging for pancreatic ductal adenocarcinoma at 3.0-T magnetic resonance: correlation with histopathology. Last author DOI 10.1097/rct.0000000000000171↗
  11. The Correlation Between Diffusion-Weighted Imaging at 3.0-T Magnetic Resonance Imaging and Histopathology for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/rct.0000000000000274↗
  12. Assessment of dynamic contrast-enhanced magnetic resonance imaging in the differentiation of pancreatic ductal adenocarcinoma from other pancreatic solid lesio… Last author DOI 10.1097/rct.0000000000000120↗
  13. The effect of gadolinium chelate contrast agent on diffusion-weighted imaging of pancreatic ductal adenocarcinoma. Last author DOI 10.1177/0284185112471795↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tiansong Xie · 7 shared papers, 2020–2026 · strength 1.73
  2. Zehua Zhang · 5 shared papers, 2024–2026 · strength 1.30
  3. Yi Chen · 2 shared papers, 2026 · strength 0.60
  4. Wei Liu · 2 shared papers, 2026 · strength 0.60
  5. Wei Liu · 2 shared papers, 2024–2025 · strength 0.49
  6. Huayu Yang · 1 shared paper, 2025 · strength 0.42
  7. Wei Liu · 1 shared paper, 2025 · strength 0.42
  8. Lei Chen · 1 shared paper, 2026 · strength 0.32
  9. Yi Chen · 1 shared paper, 2025 · strength 0.28
  10. Wei Liu · 1 shared paper, 2025 · strength 0.28
  11. Kefu Liu · 4 shared papers, 2013–2015 · strength 0.27
  12. Ping Xie · 3 shared papers, 2014–2015 · strength 0.21
  13. Shengli He · 1 shared paper, 2019 · strength 0.11
  14. Jie Shen · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.